NGM Bio to Present at Two Upcoming Investor Conferences
Rhea-AI Summary
NGM Biopharmaceuticals, focused on transformative therapeutics, announced that CEO David J. Woodhouse will present an overview and business update at two investor conferences. The events are scheduled for June 3, 2020, at the Jefferies Virtual Healthcare Conference at 3:30 pm ET, and June 10, 2020, at the Goldman Sachs 41st Annual Global Healthcare Conference at 1:20 pm ET. A live webcast will be available on their website, with a replay accessible for 30 days post-event.
Positive
- None.
Negative
- None.
News Market Reaction – NGM
In the trading session that priced this news, NGM declined 0.76%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., May 29, 2020 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), a biotechnology company focused on developing transformative therapeutics for patients, today announced that David J. Woodhouse, Ph.D., Chief Executive Officer, will present an overview of the company and provide a business update at two upcoming investor conferences.
Wednesday, June 3, 2020
Event: Jefferies Virtual Healthcare Conference
Time: 3:30 pm ET
Wednesday, June 10, 2020
Event: Goldman Sachs 41st Annual Global Healthcare Conference
Time: 1:20 pm ET
A live webcast of these presentations will be available under the Investors and Media section of NGM’s website at https://ir.ngmbio.com/events-presentations. A replay of the presentation will be archived on NGM’s site for 30 days following the event.
About NGM Biopharmaceuticals, Inc.
NGM is a biopharmaceutical company focused on developing novel therapeutics based on scientific understanding of key biological pathways underlying cardio-metabolic, liver, oncologic and ophthalmic diseases. We leverage our biology-centric drug discovery approach to uncover novel mechanisms of action and generate proprietary insights that enable us to move rapidly into proof-of-concept studies and deliver potential first-in-class medicines to patients. At NGM, we aspire to operate one of the most productive research and development engines in the biopharmaceutical industry, with multiple programs in clinical development. Visit us at www.ngmbio.com for more information.
| Investor Contacts: Sylvia Wheeler and Alexandra Santos swheeler@wheelhouselsa.com asantos@wheelhouselsa.com ir@ngmbio.com | Media Contact: Liz Melone media@ngmbio.com |